News >

Relugolix Elicits High Response Rate in Advanced Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Nov 19, 2019

 Neal Shore, MD, medical director of the Carolina Urologic Research Center and HERO Program Steering Committee Member

Neal Shore, MD

Treatment with relugolix achieved a high rate of sustained testosterone suppression to castrate levels in patients with androgen-sensitive advanced prostate cancer, meeting the primary endpoint of the phase III HERO trial (NCT03085095).1

Specifically, results showed that in the primary endpoint responder analysis, 96.7% (95% CI, 94.9%-97.9%) of men receiving once-daily, oral relugolix achieved sustained testosterone suppression to castrate levels (≤50 ng/dL) from weeks 5 through 48. The endpoint was met if the lower bound of the 95% confidence interval of the response rate was ≥90%. 

The data will serve as support for a new drug application (NDA) to the FDA, which is anticipated to be submitted in the second quarter for 2020, Myovant Sciences, the developer of the oral gonadotropin-releasing hormone (GnRH) receptor antagonist, stated in a press release. The company added that the findings will also be included in future regulatory submissions in Europe and Japan.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication